{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:36:20Z","timestamp":1772818580002,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.metabol.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T01:47:07Z","timestamp":1490924827000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients"],"prefix":"10.1016","volume":"71","author":[{"given":"Jos\u00e9 M.","family":"Gallego-Escuredo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Karuna","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan C.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Gracia","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma del Mar","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.03.014_bb0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2017.03.014_bb0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bcp.12676","article-title":"Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study","volume":"80","author":"Dong","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2017.03.014_bb0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0020","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1097\/QAD.0b013e3283400088","article-title":"Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients","volume":"24","author":"Domingo","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0b013e318271c2c7","article-title":"Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients","volume":"61","author":"Gallego-Escuredo","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2017.03.014_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2017.03.014_bb0035","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1073\/pnas.1200797109","article-title":"Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2017.03.014_bb0040","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1210\/en.2014-1083","article-title":"FGF-21 and skeletal remodeling during and after lactation in C57BL\/6J mice","volume":"155","author":"Bornstein","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2017.03.014_bb0045","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cmet.2015.09.010","article-title":"A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone Resorption","volume":"22","author":"Wang","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00774-016-0745-z","article-title":"Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats","volume":"35","author":"Charoenphandhu","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/00365513.2014.992942","article-title":"Fibroblast growth factor-21 concentration in serum and synovial fluid is associated with radiographic bone loss of knee osteoarthritis","volume":"75","author":"Li","year":"2015","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.metabol.2017.03.014_bb0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bone.2015.04.001","article-title":"Serum FGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa","volume":"77","author":"Fazeli","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.03.014_bb0070","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s00198-013-2464-9","article-title":"Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?","volume":"24","author":"Lee","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.03.014_bb0075","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0080","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/656412","article-title":"Bone disease in HIV infection: a practical review and recommendations for HIV care providers","volume":"51","author":"McComsey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.metabol.2017.03.014_bb0085","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","article-title":"Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system","volume":"93","author":"Triant","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/COH.0000000000000028","article-title":"The effects of untreated and treated HIV infection on bone disease","volume":"9","author":"Cotter","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e318295eb1d","article-title":"Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals","volume":"63","author":"Brown","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2017.03.014_bb0100","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e32833c93fe","article-title":"High prevalence of reduced bone mineral density in primary HIV-1-infected men","volume":"24","author":"Grijsen","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/infdis\/jis687","article-title":"Low bone mineral density, regardless of HIV status, in men who have sex with men","volume":"207","author":"Grijsen","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.metabol.2017.03.014_bb0110","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir\u2013lamivudine versus tenofovir\u2013emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.metabol.2017.03.014_bb0115","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.metabol.2017.03.014_bb0120","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/jc.2012-3686","article-title":"Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study","volume":"98","author":"Cotter","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0125","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3851\/IMP1874","article-title":"Bone turnover, osteoprotegerin\/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens","volume":"16","author":"Brown","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.metabol.2017.03.014_bb0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hiv.12123","article-title":"Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks","volume":"15","author":"Bloch","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.metabol.2017.03.014_bb0135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0140","first-page":"145","article-title":"Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy","volume":"84","author":"Aukrust","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0145","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1210\/jc.2011-0591","article-title":"Stable bone density in HAART-treated individuals with HIV: a meta-analysis","volume":"96","author":"Bolland","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ajcn\/64.5.685","article-title":"A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue","volume":"64","author":"Lemieux","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2017.03.014_bb0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2017.03.014_bb0160","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/clinchem\/41.5.717","article-title":"Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin","volume":"41","author":"Sugiuchi","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2017.03.014_bb0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2017.03.014_bb0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00198-004-1699-x","article-title":"Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover","volume":"16","author":"Indridason","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.03.014_bb0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1570162X1401151102143222","article-title":"Changes in serum markers of inflammation and endothelial activation in HIV-infected antiretroviral naive patients starting a treatment with abacavir\u2013lamivudine or tenofovir\u2013emtricitabine plus efavirenz","volume":"14","author":"Calza","year":"2016","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.metabol.2017.03.014_bb0180","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/jc.2007-0646","article-title":"CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)\/RANK ligand\/osteoprotegerin: clinical implications","volume":"92","author":"Vega","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00774-003-0461-3","article-title":"Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios","volume":"22","author":"Jorgensen","year":"2004","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.metabol.2017.03.014_bb0190","first-page":"409","article-title":"Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis","volume":"41","author":"Grigorie","year":"2003","journal-title":"Rom J Intern Med"},{"key":"10.1016\/j.metabol.2017.03.014_bb0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1468-1293.2005.00278.x","article-title":"Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients","volume":"6","author":"Seminari","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.metabol.2017.03.014_bb0200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00065","article-title":"The starvation hormone, fibroblast growth factor-21, extends lifespan in mice","volume":"1","author":"Zhang","year":"2012","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.metabol.2017.03.014_bb0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/QAI.0b013e31829bdb67","article-title":"Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy","volume":"64","author":"Gallego-Escuredo","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2017.03.014_bb0210","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/00002030-200206140-00009","article-title":"Reduced intravertebral bone marrow fat in HIV-infected men","volume":"16","author":"Huang","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0215","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mrm.20205","article-title":"Fat fractions and spectral T2 values in vertebral bone marrow in HIV- and non-HIV-infected men: a 1H spectroscopic imaging study","volume":"52","author":"Mulkern","year":"2004","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.metabol.2017.03.014_bb0220","doi-asserted-by":"crossref","first-page":"26060","DOI":"10.1074\/jbc.M112.343707","article-title":"Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate","volume":"287","author":"Wu","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2017.03.014_bb0225","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/00325481.2015.1015927","article-title":"Lipodystrophy: syndrome of severe insulin resistance","volume":"127","author":"Bindlish","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.metabol.2017.03.014_bb0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/COH.0000000000000275","article-title":"Does systemic inflammation and immune activation contribute to fracture risk in HIV?","volume":"11","author":"McGinty","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.metabol.2017.03.014_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.01.001","article-title":"Current topics in HIV pathogenesis, part 2: inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects","volume":"28","author":"Aounallah","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.metabol.2017.03.014_bb0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cytogfr.2015.09.001","article-title":"Current topics in HIV-1 pathogenesis: the emergence of deregulated immuno-metabolism in HIV-infected subjects","volume":"26","author":"Dagenais-Lussier","year":"2015","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:15:10Z","timestamp":1758428110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517301014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":48,"alternative-id":["S0026049517301014"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.03.014","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}